Scott Hutton is Chief Executive Officer and Director of Biodesix, a leading diagnostic solutions company based in Colorado. He is a public company CEO with full P&L responsibility and Board engagement experience, leading strategy, capital allocation, and operational execution within a highly regulated healthcare environment. His leadership includes oversight of capital markets activities, financial planning and controls, financial reporting, and enterprise risk management. He leads with a clear philosophy: help people, give back, and improve lives through better health outcomes. Hutton is also the author of Hutton’s Huddle, a personal leadership WebLog focused on workforce and culture leadership, building high-performance teams, driving accountability, and leading with purpose.
Mr. Hutton is an accomplished healthcare executive with nearly 30 years of experience across diagnostics, biotechnology, and medical devices. He has deep expertise in scaling commercial-stage businesses that redefine standards of care and improve patient outcomes at scale. His leadership spans global commercialization, reimbursement and pricing strategy, regulatory and quality systems, and end-to-end operations, including manufacturing and supply chain. He is particularly focused on translating innovation into commercial adoption, aligning clinical value, reimbursement, and go-to-market execution to drive sustained growth. His experience also includes advanced data and technology capabilities, including bioinformatics, artificial intelligence, and the integration of multiomics platforms—encompassing genomics, proteomics, and radiomics—to support precision diagnostics and clinical decision-making.
Under his leadership, Biodesix has accelerated adoption of its Lung Diagnostics portfolio, expanded its Development Services business, and driven significant cultural, operational, and financial transformation. The company has delivered sustained revenue growth, achieved industry-leading gross margins, and reached its first quarter of positive Adjusted EBITDA in 2025—demonstrating operating leverage and the scalability of its commercial model. He has overseen complex clinical and laboratory environments, including CLIA-certified, high-complexity laboratory operations, with responsibility for lab quality systems, workflow optimization, and automation. In 2020, Mr. Hutton successfully guided the company through its initial public offering (Nasdaq: BDSX). Biodesix has since been recognized as one of The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025, a USA Today Top Workplace (2026), a Denver Post Top Workplace (2025), and an Inc. Magazine Best Workplace (2024), reflecting three consecutive years of top workplace culture recognitions.
Prior to becoming CEO in 2020, Mr. Hutton served as Chief Operating Officer of Biodesix. Before Biodesix, he held senior executive roles at Spectranetics, where he served as Senior Vice President and General Manager of the Vascular Interventions business with global P&L responsibility, overseeing commercialization, operations, and manufacturing, and playing a key leadership role in the company’s $2.2 billion acquisition by Royal Philips. He also spent more than 16 years at Medtronic in progressively senior leadership roles, including Vice President & General Manager of the Neurosurgery business, with responsibility for a billion-dollar global revenue portfolio spanning product innovation, reimbursement and pricing, regulatory and quality compliance, supply chain performance, and commercial execution.
Mr. Hutton brings extensive expertise in corporate strategy, mergers and acquisitions (M&A), integration execution, and global product commercialization within highly regulated environments. His regulatory experience includes oversight of FDA and international regulatory pathways, post-market surveillance, and evidence-development strategies supporting clinical adoption and market access. He has built and led high-performing teams responsible for more than 50 product launches, that are now annually impacting tens of millions of patients worldwide. His experience spans the full business lifecycle, from clinical development and regulatory approval through operational scale-up, market access, and sustained commercial growth, and includes experience relevant to Board governance, strategic planning, audit and risk oversight, and capital allocation.
Mr. Hutton has extensive Board and Corporate Governance experience. He currently serves on the boards of The Coalition for 21st Century Medicine and Eximis Surgical, and is a member of the Dean’s Leadership Council at Purdue University College of Health and Human Sciences. His prior board and advisory roles include the Purdue University Public Health External Advisory Board, the Colorado BioScience Association, Aqueduct Critical Care, and Visualase.
Mr. Hutton has received numerous honors recognizing his leadership and industry impact, including The Healthcare Technology Report’s Top Healthcare Technology CEOs (2025) and Top 25 Biotech and Life Sciences Executives (2025), along with multiple prior Top 25 Biotech CEO distinctions. He is also a recipient of Purdue University’s Distinguished Alumni and Distinctive Service Awards, a Purdue Old Master (2021), and a Sigma Chi Significant Sig (2021). He earned a Bachelor of Arts in Health and Kinesiology from Purdue University.